Shilpa Medicare Q1FY27 Revenue Surges 43% to ₹469 Crore, EBITDA Up 42%
Shilpa Medicare reported a 43% YoY revenue growth to ₹469 crore and a 42% YoY EBITDA increase to ₹139 crore for Q1FY27. PAT surged 115% YoY to ₹101 crore. Growth was driven by API, Formulations, and Biologics segments. The company also noted a credit rating upgrade to AA-.
The announcement details significant financial growth, record-breaking quarterly results, strategic pipeline advancements, and a credit rating upgrade, all of which are material and positive developments for the company's stakeholders.
The company reported record quarterly revenue and EBITDA with significant YoY growth, alongside a substantial increase in PAT and a credit rating upgrade, indicating strong financial performance and positive business outlook.
Shilpa Medicare Limited has announced its financial results for the quarter ended June 30, 2026 (1QFY27). The company reported its highest-ever quarterly revenue at ₹469 crore, marking a significant 43% year-on-year (YoY) increase. EBITDA also reached a record high of ₹139 crore, a 42% YoY growth, with EBITDA margins maintained at a robust 30%. Profit After Tax (PAT) saw a substantial increase of 115% YoY, reaching ₹101 crore.
The company's performance was driven by healthy growth across its three key verticals: API, Formulations, and Biologics. API revenue grew by approximately 15% YoY, with both captive and non-captive segments showing consistent improvement, particularly the Specialty CDMO division. The Formulations business delivered over 100% YoY revenue growth, with notable contributions from the US and Europe markets, and a strong domestic performance boosted by the launch of NorUDCA.
Shilpa Medicare highlighted its strategic advancements in novel products and pipeline development. This includes the first-in-class treatment for Non-alcoholic Fatty Liver Disease (NAFLD) in India, NorUDCA, and progress in complex generic formulations like Rotigotine Transdermal Patch and Ondansetron Long-Acting Injection. The Biologics segment is focusing on a high-value biosimilars portfolio, including partnerships for Nivolumab and development of its first ADC biosimilar.
Management commentary emphasized the strong operating discipline and strategic direction, reconfirming the company's integrated approach combining R&D, manufacturing, and a growing product portfolio. The company also noted its credit rating upgrade from A+ to AA-, reflecting its strengthening balance sheet and improving return ratios, with ROCE trending upwards. Shilpa Medicare remains confident in delivering a stronger FY27.
What to do with a filing like this
Shilpa Medicare Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Shilpa Medicare Limited. Read the original for the full detail.